Cmed Group Showcases Trial Delivery Capabilities at DIA 2013

HORSHAM, UK — June 3, 2013 – Cmed Group will showcase its full-service CRO capabilities at the DIA’s Annual Meeting 2013 (June 23-27, 2013, Boston Convention and Exhibition Center, Boston, Massachusetts, USA) as well as demonstrate the latest version of Timaeus, its innovative, cloud-based eClinical platform to manage data from Study Design through Reporting.

 

Through the coupling of full service trial delivery teams and trusted technology, Cmed Group has a proven track record of helping the biopharmaceutical industry design and deliver both innovative and traditional early phase I to IIb clinical trials, as well as increasingly being asked by clients to take on their phase III projects.

 

Cmed has seen accelerating demand for strategic advice and drug development consulting, both in terms of study design and CDP development, and therefore has been expanding its in-house Drug Development Consulting, Regulatory & Medical Affairs Group. Visitors to Booth #858 can take advantage of obtaining expert advice on various topics from this highly experienced team, including Geoff Fatzinger, Vice President of Global Medical and Regulatory Affairs. Visitors can also discover how the company’s skilled Project Managers and geographically based CRAs deliver projects to time, budget and quality, as well as hear about Cmed’s biometrics solutions for fullservice trials or as a standalone service.

 

In addition, visitors will receive personal demonstrations of Cmed’s impressive e-clinical technology, Timaeus, and learn how study teams can quickly, easily and cost‐effectively build and manage clinical research studies. Timaeus features new streamlined interfaces with improved query management and source data verification workflow. Investigators and Monitors are able to work from a dynamic to-do list while Monitors quickly access study metrics from a new custom dashboard.  Cmed will also highlight how Timaeus Guided Trial Builder enables non-programmers to very rapidly build entire trials, including visit schedules, pages and edit checks. Adding Guided Trial Builder to Timaeus’ on-demand deployment capabilities enables study teams to build validated trials from a global library of standards, eliminating QC and manual hand-off delays during the study start up process.

 

To find out more about Cmed’s CRO services and Timaeus, visit Booth #858 at DIA 2013 Annual Meeting at the Boston Convention and Exhibition Center on June 23-27, 2013. Alternatively, visit www.cmedgroup.com for more information.

 

– ends-

 

About Cmed Group

Cmed Group is an innovative clinical trials services and advanced software provider which includes two divisions: Cmed Clinical Services, a full-service clinical research organization, and Cmed Technology, an eClinical technology provider. Central to our business is Timaeus, a unified on-demand platform that supports Study Design through Reporting.

 

About Cmed Clinical Services

Cmed Clinical Services is a long-established, flexible CRO offering project management, clinical monitoring, data management, biostatistics, medical affairs, regulatory, consulting, and medical writing services. While Cmed’s area of specialization is the design and delivery of both innovative and traditional phase I to IIb clinical trials, Cmed increasingly uses its experience and capabilities for existing clients phase III programs and for functional service provision of biometrics.

 

About Cmed Technology

Cmed Technology, an eClinical technology provider, offers Timaeus: a single platform for electronic trial design, paper and electronic data capture, monitoring, coding, data management and reporting. The Timaeus eClinical platform is designed to respond on-demand to the needs of investigators, data managers and study teams. Timaeus’ unique architecture uses advanced distributed cloud computing and mobile technologies to provide the freedom to manage any type of data, for any protocol, anywhere. Timaeus has been used in every phase of clinical research – including early phase, pivotal and late phase studies as well as in globally established and emerging markets – covering single-unit clinics to multi-thousand person studies